| Market Capitalization (Millions $) |
278 |
| Shares
Outstanding (Millions) |
270 |
| Employees |
194 |
| Revenues (TTM) (Millions $) |
219 |
| Net Income (TTM) (Millions $) |
-30 |
| Cash Flow (TTM) (Millions $) |
25 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Akebia Therapeutics Inc is a biopharmaceutical company that focuses on the development and commercialization of novel therapeutics for patients with kidney diseases. The company is headquartered in Cambridge, Massachusetts, and has a subsidiary in Tokyo, Japan. Founded in 2007, Akebia's mission is to make a meaningful difference in the lives of patients with chronic kidney disease (CKD) by advancing the development of innovative therapies.
The company's lead compound is vadadustat, an oral hypoxia-inducible factor (HIF) prolyl hydroxylase (PH) inhibitor that is designed to mimic the body's natural response to hypoxia (low oxygen levels) by stimulating erythropoiesis (the production of red blood cells). Kidney disease patients often suffer from anemia, which is a shortage of red blood cells, and vadadustat is aimed at treating this condition in CKD patients.
In clinical trials, vadadustat has demonstrated efficacy and safety in increasing hemoglobin levels in both incident and prevalent CKD patients with anemia. Akebia is conducting Phase 3 trials to evaluate the long-term safety and efficacy of vadadustat compared to conventional therapy with erythropoiesis-stimulating agents (ESAs) for the treatment of anemia associated with CKD.
Aside from vadadustat, Akebia is also exploring other drug candidates for the treatment of kidney diseases. These include AKB-6899, a selective dopamine D1 receptor agonist, and AKB-5169, a selective HIF-2 alpha inhibitor.
Akebia has established partnerships with several pharmaceutical companies to develop and commercialize vadadustat in various regions around the world. Partnerships include Otsuka Pharmaceutical Co. Ltd. for Japan, Mitsubishi Tanabe Pharma Corporation for Asia, and Vifor Pharma Group for Europe, Middle East, and Africa.
Overall, Akebia Therapeutics Inc is a biopharmaceutical company dedicated to developing innovative therapies for patients with kidney diseases. With its lead compound vadadustat, the company is poised to make a significant impact on the treatment of anemia in CKD patients, with the potential to improve patient outcomes and quality of life.
Company Address: 245 First Street Cambridge 2142 MA
Company Phone Number: 871-2098 Stock Exchange / Ticker: NASDAQ AKBA
|
1.78% 
201.02 %